IP Library › Granted Patent US 12,365,710
Granted Patent B2
US 12,365,710 · App. 17/282,354 · Granted Jul 22, 2025

HMGB1 protein derivatives for the removal of biofilms

Inventors: Steven David Goodman (Columbus, OH); Lauren Opremcak Bakaletz (Columbus, OH)
Assignee: Research Institute at Nationwide Children's Hospital
C07K14/47C07K16/1232C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,710
App. No.
17/282,354
Granted
Jul 22, 2025
Kind
B2
Abstract

Provided herein are derivatives of HMGB1 that have been engineered to possess the same efficacious anti-bio film activity but are smaller and do not induce inflammation.

Claims (12)

1. An isolated B Box polypeptide consisting of the amino acid sequence as shown in SEQ ID NO: 12.

2. The isolated B Box polypeptide of claim 1 , wherein the isolated B Box polypeptide is chemically synthesized.

3. A composition comprising a carrier and the isolated polypeptide of claim 1 .

4. A kit comprising the isolated polypeptide of claim 1 and instructions for use.

5. An isolated AB Box polypeptide consisting of the amino acid sequence as shown in SEQ ID NO: 8, wherein the amino acid corresponding to C106 has a C106S mutation, and wherein the AB polypeptide is chemically synthesized.

6. The isolated AB Box polypeptide of claim 5 , comprising one or more amino acid mutations at an amino acid position selected from K12, C23, C45, or K114.

7. A method for inhibiting, competing or titrating the binding of a DNABII polypeptide or protein to a microbial DNA, comprising contacting the DNABII polypeptide or protein or the microbial DNA with the polypeptide of claim 1 , thereby inhibiting, competing or titrating the binding of the DNABII protein or polypeptide to the microbial DNA.

8. A method for inhibiting, preventing or breaking down a microbial biofilm, comprising contacting the biofilm with the polypeptide of claim 1 , thereby inhibiting, preventing or breaking down the microbial biofilm.

9. The method of claim 8 , wherein the biofilm is produced by an organism selected from the group of uropathogenic Escherichia coli (UPEC), Klebsiella pneumonia, Burkholderia cenocepacia, S. epidermidis, Streptococcus agalactiae, Neisseria meningitidis, Treponemes denticola, Treponemes pallidum, Burkholderia cepacia, Burkholderia pseudomallei, Haemophilus influenzae (nontypeable) (NTHI), Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Mycobacterium tuberculosis or an ESKAPE pathogen.

10. A method of one or more of the following: (a) inhibiting, preventing or breaking down a biofilm in a subject, (b) inhibiting, preventing or treating a microbial infection that produces a biofilm in a subject, (c) disrupting a biofilm and clearance thereof that does not enhance or induce an inflammatory response in a subject in need thereof, or (d) treating an infection or disorder incident to the presence of a biofilm in a subject in need thereof,

the method comprising administering to the subject an effective amount of the polypeptide of claim 1 , thereby (a′) inhibiting, preventing or breaking down the microbial biofilm, (b′) inhibiting, preventing or treating a microbial infection that produces the biofilm in the subject, (c′) disrupting the biofilm and clearance thereof that does not enhance or induce an inflammatory response, or (d′) treating the infection or disorder incident to the presence of a biofilm in the subject, respectively.

11. The method of claim 10 , further comprising administering an antimicrobial.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2025
From: GOODMAN, STEVEN DAVID; BAKALETZ, LAUREN OPREMCAK
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 070899/0857 →
CONFIRMATORY LICENSE Recorded Nov 22, 2023
From: CHILDREN'S HOSPITAL COLUMBUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065666/0634 →
Continuity (2)
Provisional Application 62742102 · Oct 5, 2018
Related Publication 20210340198A1 · Nov 4, 2021
References Cited (400)
US 6551795B1 · Rubenfield et al. · 2003 [cited by applicant]
US 6663863B2 · Horvath et al. · 2003 [cited by applicant]
US 6696550B2 · Larosa et al. · 2004 [cited by applicant]
US 6846651B2 · Fleischmann et al. · 2005 [cited by applicant]
US 7241867B2 · Bakaletz et al. · 2007 [cited by applicant]
US 7413868B2 · Kauvar et al. · 2008 [cited by applicant]
US 7638282B2 · Bakaletz et al. · 2009 [cited by applicant]
US 7811591B2 · Bakaletz et al. · 2010 [cited by applicant]
US 7816086B2 · Bakaletz et al. · 2010 [cited by applicant]
US 7939344B2 · Kauvar et al. · 2011 [cited by applicant]
US 7998490B2 · Bakaletz et al. · 2011 [cited by applicant]
US 8236494B2 · Bakaletz et al. · 2012 [cited by applicant]
US 8283114B2 · Bakaletz et al. · 2012 [cited by applicant]
US 8628917B2 · Bakaletz et al. · 2014 [cited by applicant]
US 8652773B2 · Bakaletz et al. · 2014 [cited by applicant]
US 8758764B2 · Masignani et al. · 2014 [cited by applicant]
US 8933029B2 · Mcnicol et al. · 2015 [cited by applicant]
US 8999291B2 · Goodman et al. · 2015 [cited by applicant]
US 9017656B2 · Hancock et al. · 2015 [cited by applicant]
US 9034642B2 · Bakaletz et al. · 2015 [cited by applicant]
US 9155792B2 · Cottarel et al. · 2015 [cited by applicant]
US 9745366B2 · Goodman et al. · 2017 [cited by applicant]
US 10570193B2 · Kauvar et al. · 2020 [cited by applicant]
US 10595530B2 · Goodman et al. · 2020 [cited by applicant]
US 10940204B2 · Bakaletz et al. · 2021 [cited by applicant]
US 11104723B2 · Goodman et al. · 2021 [cited by applicant]
US 11248040B2 · Kauvar et al. · 2022 [cited by applicant]
US 11497780B2 · Goodman et al. · 2022 [cited by applicant]
US 11746136B2 · Goodman et al. · 2023 [cited by applicant]
US 20020132753A1 · Rosen et al. · 2002 [cited by applicant]
US 20030060410A1 · Tracey et al. · 2003 [cited by applicant]
US 20030099602A1 · Levin et al. · 2003 [cited by applicant]
US 20030229065A1 · Levy et al. · 2003 [cited by applicant]
US 20040202670A1 · Apicella · 2004 [cited by applicant]
US 20050049402A1 · Babcook et al. · 2005 [cited by applicant]
US 20050131222A1 · Fleischmann et al. · 2005 [cited by applicant]
US 20050221439A1 · Bakaletz et al. · 2005 [cited by applicant]
US 20060030539A1 · Nick et al. · 2006 [cited by applicant]
US 20060099207A1 · Wu et al. · 2006 [cited by applicant]
US 20060121047A1 · Tracey · 2006 [cited by applicant]
US 20060228384A1 · Eldridge · 2006 [cited by applicant]
US 20060240045A1 · Berthet et al. · 2006 [cited by applicant]
US 20070154529A1 · Bullerdiek · 2007 [cited by applicant]
US 20070207210A1 · Brown et al. · 2007 [cited by applicant]
US 20070264256A1 · Bakaletz et al. · 2007 [cited by applicant]
US 20070286822A1 · Sanders et al. · 2007 [cited by applicant]
US 20090029929A1 · Nakajima et al. · 2009 [cited by applicant]
US 20090297555A1 · Kemble et al. · 2009 [cited by applicant]
US 20090324651A1 · Old et al. · 2009 [cited by applicant]
US 20100166771A1 · Bakaletz et al. · 2010 [cited by applicant]
US 20100291177A1 · Hermans et al. · 2010 [cited by applicant]
US 20100310569A1 · Bakaletz et al. · 2010 [cited by applicant]
US 20110135646A1 · Bakaletz et al. · 2011 [cited by applicant]
US 20110236306A1 · Goodman et al. · 2011 [cited by applicant]
US 20110293624A1 · Bakaletz et al. · 2011 [cited by applicant]
US 20120128701A1 · Goodman et al. · 2012 [cited by applicant]
US 20120148615A1 · Masignani et al. · 2012 [cited by applicant]
US 20130017204A1 · Bakaletz et al. · 2013 [cited by applicant]
US 20130078254A1 · Bakaletz et al. · 2013 [cited by applicant]
US 20130183323A1 · Wang · 2013 [cited by applicant]
US 20140120107A1 · Bakaletz et al. · 2014 [cited by applicant]
US 20140127221A1 · Bakaletz et al. · 2014 [cited by applicant]
US 20140287426A1 · Arnold et al. · 2014 [cited by applicant]
US 20140356389A1 · Masignani et al. · 2014 [cited by applicant]
US 20150010654A1 · Arnold et al. · 2015 [cited by applicant]
US 20150086542A1 · Goodman et al. · 2015 [cited by applicant]
US 20150086561A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150110838A1 · Agrawal · 2015 [cited by applicant]
US 20150166641A1 · Goodman et al. · 2015 [cited by applicant]
US 20150197558A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150216971A1 · Rotolo et al. · 2015 [cited by applicant]
US 20150218231A1 · Bakaletz et al. · 2015 [cited by applicant]
US 20150299298A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150342848A1 · Bhushan et al. · 2015 [cited by applicant]
US 20160095316A1 · Goodman et al. · 2016 [cited by applicant]
US 20160175440A1 · Goodman et al. · 2016 [cited by applicant]
US 20160194384A1 · Goodman et al. · 2016 [cited by applicant]
US 20160237145A1 · Kauvar et al. · 2016 [cited by applicant]
US 20160244489A1 · Masignani et al. · 2016 [cited by applicant]
US 20160287630A1 · Wood et al. · 2016 [cited by applicant]
US 20160289278A1 · Bakaletz et al. · 2016 [cited by applicant]
US 20160340650A1 · Wagner et al. · 2016 [cited by applicant]
US 20170182205A1 · Zupancic et al. · 2017 [cited by applicant]
US 20170197028A1 · Goldsmith · 2017 [cited by applicant]
US 20170215417A1 · Bhushan et al. · 2017 [cited by applicant]
US 20180303900A1 · Bakaletz et al. · 2018 [cited by applicant]
US 20190000971A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20190040127A1 · Wadehra et al. · 2019 [cited by applicant]
US 20190337996A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20190338018A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20200002409A1 · Goodman et al. · 2020 [cited by applicant]
US 20200190170A1 · Kauvar et al. · 2020 [cited by applicant]
US 20210100854A1 · Goodman et al. · 2021 [cited by applicant]
US 20210139551A1 · Goodman et al. · 2021 [cited by applicant]
US 20210139610A1 · Goodman et al. · 2021 [cited by applicant]
US 20210206841A1 · Goodman et al. · 2021 [cited by applicant]
US 20210228716A1 · Bakaletz et al. · 2021 [cited by applicant]
JP 2005519998 · 2005 [cited by applicant]
JP 2006506441A · 2006 [cited by applicant]
JP 2006506467 · 2006 [cited by applicant]
JP 2008520552 · 2008 [cited by applicant]
JP 2013529893 · 2013 [cited by applicant]
JP 2013542185A · 2013 [cited by applicant]
WO WO0047104A2 · 2000 [cited by applicant]
WO WO0213826A1 · 2002 [cited by applicant]
WO WO02085295 · 2002 [cited by applicant]
WO WO03026691A1 · 2003 [cited by applicant]
WO WO03026691A2 · 2003 [cited by applicant]
WO WO2004014418A2 · 2004 [cited by applicant]
WO WO2004044001A2 · 2004 [cited by applicant]
WO WO2004046345A2 · 2004 [cited by applicant]
WO WO2004072094A2 · 2004 [cited by applicant]
WO WO2005025604A2 · 2005 [cited by applicant]
WO WO2005111066A2 · 2005 [cited by applicant]
WO WO2006017816A2 · 2006 [cited by applicant]
WO WO2006083301A2 · 2006 [cited by applicant]
WO WO2006114805A2 · 2006 [cited by applicant]
WO WO2006138527 · 2006 [cited by applicant]
WO WO2007001422A2 · 2007 [cited by applicant]
WO WO2009006699A1 · 2009 [cited by applicant]
WO WO2011123396A1 · 2011 [cited by applicant]
WO WO2012034090A1 · 2012 [cited by applicant]
WO WO2012151554A1 · 2012 [cited by applicant]
WO WO2013177596A2 · 2013 [cited by applicant]
WO WO2014016417A1 · 2014 [cited by applicant]
WO WO2014190096A1 · 2014 [cited by applicant]
WO WO2014201305A1 · 2014 [cited by applicant]
WO WO2015038339A1 · 2015 [cited by applicant]
WO WO2015048484A2 · 2015 [cited by applicant]
WO WO2015136311A1 · 2015 [cited by applicant]
WO WO2016154491A1 · 2016 [cited by applicant]
WO WO2016184795A1 · 2016 [cited by applicant]
WO WO2017023863A1 · 2017 [cited by applicant]
WO WO2017066719A2 · 2017 [cited by applicant]
WO WO2017192594A1 · 2017 [cited by applicant]
WO WO2018042385A2 · 2018 [cited by applicant]
WO WO2018050814A1 · 2018 [cited by applicant]
WO WO2018129092A1 · 2018 [cited by applicant]
WO WO2018170178A1 · 2018 [cited by applicant]
WO WO2018187615A1 · 2018 [cited by applicant]
WO WO2020006528A2 · 2020 [cited by applicant]
WO WO2020038963A1 · 2020 [cited by applicant]
WO WO2020072993A1 · 2020 [cited by applicant]
WO WO2020092554A1 · 2020 [cited by applicant]
WO WO2021007260A2 · 2021 [cited by applicant]
Blair et al., “The HMGB1 C-Terminal Tail Regulates DNA Bending”, JMB, 2016, vol. 428, pp. 4060-4072. [cited by examiner]
Starkova et al., “Structural Characteristics of High-Mobility Group Proteins HMGB1 and HMGB2 and Their Interaction with DNA” Int. J. Mol. Sci., 2023, 24, 3577. [cited by examiner]
Ota et al., “Complete sequencing and characterization of 21,243 full-length human cDNAs”, Nature Genetics, Jan. 2004, vol. 36, No., pp. 40-45. [cited by examiner]
Park et al., “Redox State-Dependent Interaction of HMGB1 and Cisplatin-Modified DNA,” Biochemistry, 2011, 50, pp. 2567-2574. [cited by applicant]
Stros et al., “A Role of Basic Residues and the Putative Intercalating Phenylalanine of the HMG-1 Box in DNA Supercoiling and Binding to Four-way DNA Junctions,” The Journal of Biological Chemistry, vol. 275, No. 46, Au… [cited by applicant]
U.S. Appl. No. 14/885,800, filed Oct. 16, 2015, Goodman et al. [cited by applicant]
U.S. Appl. No. 15/078,987, filed Mar. 23, 2016, The Research Institute at Nationwide Children's Hospital. [cited by applicant]
U.S. Appl. No. 15/999,215, filed Aug. 16, 2018, Goodman et al. [cited by applicant]
U.S. Appl. No. 16/297,094, filed Mar. 8, 2019, Goodman et al. [cited by applicant]
U.S. Appl. No. 16/475,654, filed Jul. 2, 2019, Bakaletz et al. [cited by applicant]
U.S. Appl. No. 16/475,656, filed Jul. 2, 2019, Bakaletz et al. [cited by applicant]
U.S. Appl. No. 16/492,582, filed Sep. 9, 2019, Goodman et al. [cited by applicant]
U.S. Appl. No. 17/150,731, filed Jan. 15, 2021, The Research Institute at Nationwide Children's Hospital. [cited by applicant]
Adams et al., “D-158. Epitope-mapping the immune response of children with otitis media and adults with chronic obstructive pulmonary disease to the PilA protein of nontypeable Haemophilus influenzae type IV pilus,” 107… [cited by applicant]
Adams et al., “Epitope-mapping the immune response of children with otitis media and adults with chronic obstructive pulmonary disease to the PilA protein of nontypeable Haemophilus influenzae type IV pilus,” Immunology… [cited by applicant]
Andersson et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes”, The Journal of Experimental Medicine, vol. 192, No. 4, Aug. 21, 2000, pp. 565-570. [cited by applicant]
Andersson et al., “HMGB1 is a Therapeutic Target for Sterile Inflammation and Infection”, Annual Review of Immunology, vol. 29, No. 1, Aug. 14, 2015, pp. 139-162. [cited by applicant]
Bakaletz et al., “Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chincilla,” Vaccine, v… [cited by applicant]
Bakaletz et al., “Protection against Development of Otitis Media Induced by Nontypeable Haemophilus influenzae by Both Active and Passive Immunization in a Chinchilla Model of Virus—Bacterium Superinfection,” Infecion a… [cited by applicant]
Barve et al., “Cloning and characterization of the mating type (MAT) locus from Ascochyta rabiei (teleomorph: Didymella rabiei) and a MAT phylogeny of legume-associated [cited by applicant]
Bass, J.I.F et al. (2010) “Extracellular Dna: A Major Proinflammatory Component of [cited by applicant]
Beech, I.B. et al. (2005) “Microbe-surface interactions in biofouling and biocorrosion processes,” International Microbiology 8:157-168. [cited by applicant]
Brady, R.A. et al. (2006) “Identification of [cited by applicant]
Brandstetter et al., “Antibodies Directed Against Integration Host Factor Mediate Biofilm Clearance From Nasopore,” The Laryngoscope, vol. 12, No. 11, Nov. 2013, pp. 2626-2632. [cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor—mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258, Supp… [cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor—mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258. [cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VHCDR2”, J. Immunol. May 1996, 155(9):3285-3291. [cited by applicant]
Catlin, “Extracellular Deoxyribonucleic Acid of Bacteria and a Deoxyribonuclease Inhibitor,” Science, vol. 124, Sep. 7, 1956, pp. 441-442. [cited by applicant]
Ceri, H. et al. (1999) “The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms,” Journal of Clinical Microbiology 37(6):1771-1776. [cited by applicant]
Chen, C. et al. (2004) “Substrate specificity of Helicobacter pylori histone-like HU protein is determined by insufficient stabilization of DNA flexure points,” Biochem J. 383:343-351. [cited by applicant]
Cho et al., “The modulation of the biological activities of mitochondrial histone Abf2p by yeast PKA and its possible role in the regulation of mitochondrial DNA content during glucose repression,” Biochimica et Biophys… [cited by applicant]
Coenye, T. et al. (2010) “In vitro and in vivo model systems to study microbial biofilm formation,” Journal of Microbiological Methods 83:89-105. [cited by applicant]
Cohavy, O. et al. (1999) “Identification of a Novel Mycobacterial Histone H1 Homologue (HupB) as an Antigenic Target of pANCA Monoclonal Antibody and Serum Immunoglobulin A from Patients with Cohn's Disease,” Infection … [cited by applicant]
Collarini, E.J. et al. (2009) “Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients,” J Immunol 183:6338-6345. [cited by applicant]
Dalai, B et al. (2009) “Histone-like protein H-NS regulates biofilm formation and virulence of Actinobacillus pheuropneumonia,” Microbial Pathogenesis 46:128-134. [cited by applicant]
Darouiche, R.O. et al. (2004) “Treatment of Infections Associated with Surgical Implants,” N Engl J Med 350:1422-1429. [cited by applicant]
Database Geneseq [Online] “Human high mobility group box-ABB (HMG-AB) protein, SEQ ID 29”, Databased accession No. AGB07712, Jul. 26, 2007. [cited by applicant]
Devaraj et al., “DNABII proteins play a central role in UPEC biofilm structure”, Molecular Microbiology, 2015, vol. 96, vol. 6, Jun. 2015, pp. 1119-1135. [cited by applicant]
Donlan, R.M. et al. (2002) “Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms,” Clinical Microbiology Reviews 15(2):167-193. [cited by applicant]
Durocher et al., “High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells,” Nucleic Acids Research, vol. 30, No. 2, e9, Nov. 11, 2001, 9 pages. [cited by applicant]
E. Melloni, et al., “Extracellular release of the ‘differentiation enhancing factor’, a HMG 1 protein type, is an early step in murine erythroleukemia cell differentiation” FEBS Letters 368, Year 1995, pp. 466-470. [cited by applicant]
Eboigbodin, K.E. et al. (2008) “Characterization of the Extracellular Plymeric Substances Produced by [cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections”, Pharamceuticals, vol. 3, No. 5, May 11, 2010, pp. 1374-1393. [cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections,” Pharmaceuticals, vol. 3, May 11, 2010, pp. 1374-1393. [cited by applicant]
Extended European Search Report dated Aug. 1, 2022, from application No. 19868798.0. [cited by applicant]
Falciola et al., “Mutational analysis of the DNA binding domain A of chromosomal protein HMG1,” Nucleic Acids Research, vol. 22, No. 3, Jan. 10, 1994, pp. 285-292. [cited by applicant]
Fan, Z. et al. (2002) “HMG2 Interacts with the Nucleosome Assembly Protein SET and is a Target of the Cytotoxic T-Lymphocyte Protease Granzyme A,” Molecular and Cellular Biology 22(8):2810-2820. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/493,051 dated Oct. 7, 2016, 6 pages. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/535,254 dated Jun. 9, 2017, 6 pages. [cited by applicant]
Final Office Action in U.S. Appl. No. 14/885,800 dated May 4, 2017, 17 pages. [cited by applicant]
Final Office Action in U.S. Appl. No. 15/078,987 dated Dec. 28, 2016, 12 pages. [cited by applicant]
Final Office Action on U.S. Appl. No. 14/885,800 dated May 29, 2018, 24 pages. [cited by applicant]
Final Office Action on U.S. Appl. No. 14/967,228 dated Nov. 22, 2017, 26 pages. [cited by applicant]
Final Office Action on U.S. Appl. No. 13/073,782 dated Mar. 27, 2014, 8 pages. [cited by applicant]
Final Office Action on U.S. Appl. No. 13/229,575 dated Aug. 29, 2013, 17 pages. [cited by applicant]
Final Office Action on U.S. Appl. No. 13/229,575 dated Sep. 19, 2014, 34 pages. [cited by applicant]
Garcia-Contreras et al., “Protein Translation and Cell Death: The Role of Rare tRNAs in Biofilm Formation and in Activating Dormant Phage Killer Genes,” PLoS ONE, vol. 3, No. 6, Jun. 11, 2008, e2394, 17 pages. [cited by applicant]
George et al., “Cystic fibrosis infections: treatment strategies and prospects,” FEMS Microbiol Lett., vol. 300, Jun. 15, 2009, pp. 153-164. [cited by applicant]
Gerstel et al., “Complex Regulation of csgD Promoter Activity by Global Regulatory Proteins,” Molecular Microbiology, vol. 49, No. 3, Aug. 2003, pp. 639-654. [cited by applicant]
Goldenberg et al., “Genetic and biochemical analysis of IHF/HU hybrid proteins”, BioChimie, vol. 76, No. 10-11, Jan. 1, 1994, pp. 941-950. [cited by applicant]
Good et al., “Synthetic RNA silencing in bacteria—antimicrobial discovery and resistance breaking,” Frontiers in Microbiology, vol. 2, No. 185, Sep. 12, 2011, pp. 1-11. [cited by applicant]
Goodman et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins”, Advances in Mucosal Immunology, Jun. 29, 2011, pp. 1-13. [cited by applicant]
Goodman et al., “In Vitro Selection of Integration Host Factor Binding Sites,” Journal of Bacteriology, vol. 181, No. 10, May 1999, pp. 3246-3255. [cited by applicant]
Goodman et al., “Replacement of Integration Host Factor Protein-induced DNA Bending by Flexible Regions of DNA,” The Journal of Biological Chemistry, vol. 274, No. 52, Aug. 6, 1999, pp. 37004-37011. [cited by applicant]
Goshima et al., “Chimeric HU-IHF proteins that alter DNA-binding ability,” Gene, vol. 118, No. 1, Sep. 1, 1992, pp. 97-102. [cited by applicant]
Govan et al., “Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia,” Microbiol. Rev., vol. 60, No. 3, Sep. 1996, pp. 539-574. [cited by applicant]
Granston et al., “Characterization of a Set of Integration Host Factor Mutants Deficient for DNA Binding,” J. Mol. Biol., vol. 234, Jun. 21, 1993, pp. 45-59. [cited by applicant]
Greenspan et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, vol. 17, Oct. 1999, pp. 936-937. [cited by applicant]
Gustave et al., “Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 12, No. 4, Nov. 17, 2012, pp. 384-389. [cited by applicant]
Hall-Stoodley et al., “Bacterial Biofilms: From the Natural Environment to Infectious Diseases,” Nature Reviews, Microbiology, vol. 2, Feb. 2004, pp. 95-108. [cited by applicant]
Hall-Stoodley et al., “Direct Detection of Bacterial Biofilms on the Middle-Ear [cited by applicant]
Hall-Stoodley et al., “Evolving concepts in biofilm infections”, Cellular Microbiology, vol. 11, No. 7, 2009, pp. 1034-1043. [cited by applicant]
Hall-Stoodley et al., “Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in [cited by applicant]
Haluzi et al., “Genes Coding for Integration Host Factor Are Conserve in Gram-Negative Bacteria,” Journal of Bacteriology, vol. 173, No. 19, Oct. 1991, pp. 6297-6299. [cited by applicant]
Harley et al., “The Molecular Action and Regulation of the Testis-Determining Factors, SRY (Sex-Determining Region on the Y Chromosome) and SOX9 [SRY-Related High-Mobility Group (HMG) Box 9],” Endocrine Reviews, vol. 24… [cited by applicant]
Harriman, W.D. et al. (2008) “Antibody discovery via multiplexed single cell characterization,” Journal of Immunological Methods 341:135-145. [cited by applicant]
Harrison, J.J. et al. (2010) “Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening,” Nature Protocols 5(7):1236-1254. [cited by applicant]
Haruta et al., “A possible role of histone-like DNA-binding protein of [cited by applicant]
Haruta et al., “Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation,” Laboratory Investigation, vol. 90, Apr. 2010, pp. 577-588. [cited by applicant]
Hirotaka Kazama, et al., “Immune Tolerance Induction By Apoptotic Cells Requires Caspase—Dependent Oxidation of HMGB1”, NIH Public Access, Immunity., Jul. 18, 2008, pp. 1-25. [cited by applicant]
Hoyle et al., “Bacterial Resistance to Antibiotics: The Role of Biofilms,” Prog. Drug Res., vol. 37, 1991, pp. 91-105. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2011/051107, mailed Jan. 25, 2012, 15 pages. [cited by applicant]
International Search Report and Written Opinion on PCT Application No. PCT/US2018/022508 dated Jul. 18, 2018, 17 pages. [cited by applicant]
International Search Report and Written Opinion on PCT Application No. PCT/US2019/054851 dated Feb. 28, 2020, 12 pages. [cited by applicant]
Janeway, “Manipulating the immune response to fight infection,” Immunobiology: The Immune System in Health and Disease, 5th ed.; retrieved online from https://www.ncbi.nlm.nih.gov/books/NBK27131/, 2001, 13 pages. [cited by applicant]
Jodar et al., “Development of vaccines against meningococcal disease,” Lancet, vol. 359, Apr. 27, 2002, pp. 1499-1508. [cited by applicant]
Johnson et al., “Chapter 8: Bending and Compaction of DNA by Proteins,” Protein-Nucleic Acid Interactions: Structural Biology, 2008, pp. 176-220. [cited by applicant]
Jurcisek et al., “Role of Sialic Acid and Complex Carbohydrate Biosynthesis in Biofilm Formation by Nontypeable Haemophilus influenzae in the Chinchilla Middle Ear,” Infection and Immunity, vol. 73, Jun. 2005, pp. 3210-… [cited by applicant]
Jurcisek et al., “Biofilms Formed by Nontypeable Haemophilus influenzae In Vivo Contain both Double-Stranded DNA and Type IV Pilin Protein,” Journal of Bacteriology, vol. 189, No. 10, Feb. 15, 2007, pp. 3868-3875. [cited by applicant]
Kamashev et al., “The histone-like protein HU binds specifically to DNA recombination and repair intermediates,” The EMBO Journal, vol. 19, No. 23, Oct. 13, 2000, pp. 6527-6535. [cited by applicant]
Kennedy et al., “Passive Transfer of Antiserum Specific for Immunogens Derived from a Nontypeable Haemophilus influenzae Adhesin and Lipoprotein D Prevents Otitis Media after Heterologous Challenge,” Infection and Immun… [cited by applicant]
Khrapunov, S. et al. (2006) “Binding then bending: A mechanism for wrapping DNA,” PNAS 103(51):19217-19218. [cited by applicant]
Kim et al., “Proteins Released by Helicobacter pylori In Vitro,” Journal of Bacteriology, vol. 184, No. 22, Nov. 2002, pp. 6155-6162. [cited by applicant]
Kirketerp-Moller et al., “Distribution, Organization, and Ecology of Bacteria in Chronic Wounds,” Journal of Clinical Microbiology, vol. 46, No. 8, Aug. 2008, pp. 2717-2722. [cited by applicant]
Kornblit et al., “The genetic variation of the human HMG1 gene,” Tissue Antigens, vol. 70, Apr. 12, 2007, pp. 151-156. [cited by applicant]
Kristian, S.A et al. (2003) “Alanylation of Teichoic Acids Protects [cited by applicant]
Kyd et al., “Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens to Induce Clearance of Nontypeable Haemophilus influenzae from the Rat Middle Ear and Lungs as Well as from the Chi… [cited by applicant]
Labbé et al., “Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-β and Wnt pathways,” Proc. Natl. Acad. Sci. USA, vol. 9… [cited by applicant]
Lebeaux et al., “From in vitro to in vivo Models of Bacterial Biofilm-Related Infections,” Pathogens, vol. 2, May 13, 2013, pp. 288-356. [cited by applicant]
Lee, H. et al. (2010) Analysis of nuclear high mobility group box I (HMGBI)-binding proteins in colon cancer cells: clustering with proteins involved in secretion and extranuclear function. J Proteome Res 9: 4661-70. [cited by applicant]
Li et al., “Retroviral cDNA Integration: Stimulation by HMG | Family Proteins,” Journal of Virology, vol. 74, No. 23, Dec. 2000, pp. 10965-10974. [cited by applicant]
Liu et al., “The essentiality and involvement of [cited by applicant]
Liu, D. et al. (2008) “Histone-like DNA binding protein of [cited by applicant]
Lunsford et al., “DNA-Binding Activities in [cited by applicant]
Lutz, H.U. et al. (1990) “Covalent binding of detergent-solubilized membrane glycoproteins to ‘Chemobond’ plates for ELISA,” Journal of Immunological Methods 129:211-220. [cited by applicant]
M. Elizabeth Brockson et al., “Evaluation of the kinetics and mechanism of action anti-integration host factor-mediated disruption of bacterial biofilms: Anti-IHF-mediated biofilm collapse”, Molecular Microbiology., Aug… [cited by applicant]
Mann, E.E. et al. (2009) “Modulation of eDNA Release and Degradation Affects [cited by applicant]
Martinez-Antonio A et al. (2008), “Functional organization of [cited by applicant]
Meluleni et al., (1995) “Mucoid Pseudomonas aeruginosa Growing in a Biofilm In Vitro are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule but Not by Antibodies Produced During Chronic Lung Infection … [cited by applicant]
Mo Freire, et al., “A Bacterial Biofilm Induced Oral Osteolytic Infection Can be Successfully Treated by Immuno-Targeting an Extracellular Nucleoid Associated Protein”, Mol Oral Microbiol. Feb. 2017, p. 1-21. [cited by applicant]
Mouw et al., “Shaping the Borrelia burgdorferi genome: crystal structure and binding properties of the DNA-bending protein Hbb,” Molecular Microbiology, vol. 63, No. 5, Jan. 22, 2007, pp. 1319-1330. [cited by applicant]
Mukherjee et al., “Quantitative protein expression and cell surface characteristics of [cited by applicant]
Murphy et al., “Microbial Interactions in the Respiratory Tract,” The Pediatric Infectious Disease Journal, vol. 28, No. 10, Oct. 2009, pp. S121-S126. [cited by applicant]
Murphy, T.F. et al. (2002) “Biofilm formation by nontypeable Haemophilus influenzae: strain variablitiy, outer membrane antigen expression and role of pili,” BMC Microbiology 2:7, 1-8. [cited by applicant]
Nakamura et al., “HMG Box A in HMG3 Protein Functions as a Mediator of DNA Structural Alteration Together with Box B,” J. Biochem., vol. 129, No. 4, Feb. 5, 2001, pp. 643-651. [cited by applicant]
Nash et al., “Overproduction of [cited by applicant]
NCBI Gen Bank Accession No. ACE63256 (Apr. 1, 2009), 2 pages. [cited by applicant]
NCBI GenBank Accession No. BAA03950 (Feb. 16, 2008), 2 pages. [cited by applicant]
NCBI GenBank Accession No. CAA47740 (Nov. 11, 1998), 1 page. [cited by applicant]
NCBI GenBank Accession No. CAA49169 (Feb. 5, 2003), 2 pages. [cited by applicant]
NCBI Genebank: P0A6Y1 (Sep. 13, 2005), 7 pages. [cited by applicant]
Non-Final Office Action dated Oct. 13, 2021, from U.S. Appl. No. 16/492,582. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/493,051, mailed Oct. 8, 2015, 8 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/493,051 dated Mar. 12, 2015, 8 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 13/073,782, dated Jun. 10, 2013, 15 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/493,051 dated Apr. 28, 2016, 7 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 14/885,800 dated Oct. 31, 2016, 22 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/078,987 dated Jul. 14, 2016, 15 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/078,987 dated Jun. 14, 2017, 26 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 15/078,987, mailed Mar. 16, 2018, 18 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 13/073,782, dated Jun. 25, 2014, 5 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 13/229,575, dated Jan. 10, 2013, 18 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 13/229,575 dated Mar. 31, 2014, 32 pages. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 14/535,254 dated Mar. 25, 2016, 7 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/493,051 dated Jan. 10, 2017, 4 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/535,254 dated Jan. 26, 2018, 9 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/535,254 dated Jul. 10, 2017, 5 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/535,254 dated Sep. 9, 2015, 10 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/885,800 dated Dec. 15, 2017, 16 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/967,228 dated May 19, 2017, 21 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/535,254 dated Aug. 12, 2016, 8 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 14/885,800 dated Aug. 8, 2019, 9 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 15/744,713 dated Nov. 8, 2019, 12 pages. [cited by applicant]
Notice of Allowability for U.S. Appl. No. 13/073,782 dated Mar. 4, 2015, 4 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 14/493,051 dated Apr. 25, 2017, 8 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 13/073,782, dated Aug. 19, 2014, 11 pages. [cited by applicant]
Notice of Allowance on U.S. Appl. No. 14/493,051 dated Jan. 27, 2017, 9 pages. [cited by applicant]
Notice of Allowance on U.S. Appl. No. 14/885,800 dated Nov. 13, 2019, 8 pages. [cited by applicant]
Novotny et al., “Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates,” Vaccine, vol. 28, No. 1, pp. 2… [cited by applicant]
Novotny et al., “Structural Stability of Burkholderia cenocepacia Biofilms is Reliant on eDNA Structure and Presence of a Bacterial Nucleic Acid Binding Protein,” Plos One, vol. 8, No. 6, e67629, Jun. 2013, 15 pages. [cited by applicant]
Novotny et al., “Detection and characterization of pediatric serum antibody to the Omp P5-homologous adhesin of nontypeable Haemophilus influenzae during acute otitis media,” Vaccine, vol. 20, No. 29-30, Jun. 8, 2002, p… [cited by applicant]
Novotny et al., “Epitope mapping of the Outer Membrane Protein P5-Homologous Fimbrin Adhesin of Nontypeable Haemophilus influenzae,” Infection and Immunity, vol. 68, No. 4, Apr. 2000, pp. 2119-2128. [cited by applicant]
Novotny et al., “Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae,… [cited by applicant]
Novotny et al., “The Fourth Surface-Exposed Region of the Outer Membrane Protein P5-Homologous Adhesin of the Nontypable Haemophilus influenzae is an Immunodominant But Nonprotective Decoying Epitope,” The Journal of Im… [cited by applicant]
Novotny, et al., “Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization”, Vaccine 31, Jul.… [cited by applicant]
Novotny, et al., “Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae”, Mucosal Immunol vol. 5 No. 1, Jul. 2011, pp… [cited by applicant]
Novotny, et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo”, EBioMedicine 10 (2016), pp. 33-44. [cited by applicant]
Oberto et al., “Histones, HMG, HU, IHF: Même combat,” Biochimie, vol. 76, 1994, pp. 901-908. [cited by applicant]
Ordway et al., “Evaluation of Standard Chemotherapy in the Guinea Pig Model of [cited by applicant]
Orlova, V.V. et al., “A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin”, EMBO J, vol. 26, No. 4, Year 2007, pp. 1129-1139. [cited by applicant]
Otto, “ [cited by applicant]
Paull, T.T., Haykinson, M.J., and Johnson, R.C., “The nonspecific DNA-binding and -bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures”, Genes Dev 7, Year 1993, pp. 1521-1534. [cited by applicant]
PDB ID: 1IHF: Rice, P.A. et al. (1996), 1 page; retrieved online from http://www.rcsb.org/pdb/explore.do?structureld=IHF, 2 pages. [cited by applicant]
Pedulla et al., “A novel host factor for integration of mycobacteriophage L5,” Proc. Natl. Acad. Sci. USA, vol. 93, Dec. 1996, pp. 15411-15416. [cited by applicant]
Penzo, M. et al., “Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis”, J Immunol 184, Apr. 15, 2010, pp. 4497-4509. [cited by applicant]
Percival, S.L. et al. (2015) “Biofilms and Wounds: An Overview of the Evidence,” Advances in Wound Care 4(7):373-381. [cited by applicant]
Petersen et al., “Biofilm Mode of Growth of [cited by applicant]
Pethe et al., “ [cited by applicant]
Pistoia, V. and Raffaghello, L., “Damage-associated molecular patterns (DAMPs) and mesenchymal stem cells: a matter of attraction and excitement”, Eur J Immunol 41, Year 2011, pp. 1828-1831. [cited by applicant]
Prymula et al., “ [cited by applicant]
Ranzato, E., Patrone, M., Pedrazzi, M., and Burlando, B. (2009) HMGbl promotes scratch wound closure ofHaCaT keratinocytes via ERKI/2 activation. Mal Cell Biochem 332: 199-205. [cited by applicant]
Rice et al., “Crystal Structure of an IHF-DNA Complex: A Protein-Induced DNA U-Turn,” Cell, vol. 87, No. 7, pp. 1295-1306 (Dec. 27, 1996). [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, vol. 79, No. 6, Mar. 1982, pp. 1979-1983. [cited by applicant]
Rui Kang1, et al., “HMGB1 in Health and Disease”, Mol Aspects Med., Dec. 2014, pp. 1-226. [cited by applicant]
Sapi et al., “Characterization of Biofilm Formation by Borrelia burgdorferi In Vitro,” PLOS One, vol. 7, No. 10, Oct. 2012, pp. 1-11. [cited by applicant]
Schwartz, K. et al. (2012) “Functional Amyloids Composed of Phenol Soluble Modulins Stabilize [cited by applicant]
Segall et al., “Architectural elements in nucleoprotein complexes: interchangeability of specific and non-specific DNA binding proteins,” The EMBO Journal, vol. 13, No. 19, 1994, pp. 4536-4548. [cited by applicant]
Shahrooei et al., “Inhibition of [cited by applicant]
Singh et al., “Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms,” Nature, vol. 407, No. 12, Oct. 12, 2000, pp. 762-764. [cited by applicant]
Skolnick, J. et al. (2000) “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotechnology 18:34-39. [cited by applicant]
Smith et al., “Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid,” Cell, vol. 85, Apr. 19, 1996, pp. 229-236. [cited by applicant]
Stefania Mardente, et al., “HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells”, Oncology Reports, vol. 28, Jul. 9, 2012, pp. 2285-2289. [cited by applicant]
Stinson, M.W. et al. (1998) “ [cited by applicant]
Stoltz et al., “Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth,” www.ScienceTranslationMedicine.org, vol. 2, No. 29, Apr. 28, 2010, pp. 1-8. [cited by applicant]
Stros et al., “The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins,” Cell. Mol. Life Sci., vol. 64, No. 19-20, Jun. 29, 2007, pp. 2590-2606. [cited by applicant]
Sun et al., “Inhibition of Biofilm Formation by Monoclonal Antibodies against [cited by applicant]
Swinger et al., “IHF and HU: flexible architects of bent DNA,” Current Opinion in Structural Biology, vol. 14, No. 1, 2004, pp. 28-35. [cited by applicant]
Takeda, “Polyhistidine Affinity Chromatography for Purification and Biochemical Analysis of Fungal Cell Wall-Degrading Enzymes,” Affinity Chromatography, Dr. Sameh Magdeldin (Ed.), ISBN: 978-953-51-0325-7, In Tech, 2012… [cited by applicant]
Tang et al., “High Mobility Group Box 1 (HMGB1) Activates an Autophagic Response to Oxidative Stress”, Antioxidants & Redox Signaling, vol. 15, No. 8, Oct. 15, 2011 (accepted Mar. 10, 2011), pp. 2185-2195. [cited by applicant]
Taudte et al., “Alanine mutagenesis of high-mobility-group-protein-1 box B (HMG1-B),” Biochem. J., vol. 347, Feb. 25, 2000, pp. 807-814. [cited by applicant]
Teter et al., “DNA Bending and Twisting Properties of Integration Host Factor Determined by DNA Cyclization,” Plasmid, vol. 43, 2000, pp. 73-84. [cited by applicant]
Tetz et al., “Effect of DNase and Antibiotics on Biofilm Characteristics,” Antimicrobial Agents and Chemotherapy, vol. 53, No. 3, Mar. 2009, pp. 1204-1209. [cited by applicant]
Thomas, “HMG1 and 2: architectural DNA-binding proteins,” Biochemical Society Transactions, vol. 29, Pt. 4, Apr. 12, 2001, pp. 395-401. [cited by applicant]
US Final Office Action dated Apr. 8, 2022, from U.S. Appl. No. 16/492,582. [cited by applicant]
US Notice of Allowance dated Sep. 7, 2022, from U.S. Appl. No. 16/492,582. [cited by applicant]
Vajdos et al. “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, J Mol. Biol., Jul. 5, 2002, 320(2), pp. 415-428. [cited by applicant]
Van Schaik et al., “DNA Binding: a Novel Function of [cited by applicant]
Wang, H. et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, pp. 248-251. [cited by applicant]
Wei Gong, et al., “Amino acid residues 201-205 in C-terminal acidic tail region plays a crucial role in antibacterial activity of HMGB1”, Journal of Biomedical Science, Sep. 14, 2009, pp. 1-10. [cited by applicant]
Whitchurch et al., “Extracellular DNA Required for Bacterial Biofilm Formation,” Science, vol. 295, No. 5559, Feb. 22, 2002, p. 1487, 1 page. [cited by applicant]
Whitchurch et al., “Extracellular DNA Required for Bacterial Biofilm Formation,” Science, vol. 295, No. 5559, Feb. 22, 2002, Supplementary Material, 2 pages. [cited by applicant]
Winters et al., “Isolation and Characterization of a [cited by applicant]
Winther et al., “Location of Bacterial Biofilm in the Mucus Overlying the Adenoid by Light Microscopy,” Head & Neck Surgery, vol. 135, No. 12, Dec. 2009, pp. 1239-1245. [cited by applicant]
Yang, D., Chen, Q., Yang, H., Tracey, K.J., Bustin, M., and Oppenheim, J.J., “High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin”, J Leukoc Biol 81, Ja… [cited by applicant]
Yang, H et al., “Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)”, Mol Med 18, Year 2012, pp. 250-259. [cited by applicant]
Yoshida, M. (1996) Seikagaku Biochemistry 68(12):1829-1834. [cited by applicant]
Zetterstrom, C.K., Strand, M.L., and Soder, O., “The high mobility group box chromosomal protein 1 is expressed in the human and rat testis where it may function as an antibacterial factor”, Hum Reprod 21, Year 2006, pp… [cited by applicant]
Zimmerli et al., “Pathogenesis of Foreign Body Infection: Description and Characteristics of an Animal Model,” The Journal of Infectious Diseases, vol. 146, No. 4, Oct. 1982, pp. 487-497. [cited by applicant]
Zimmerli, W. et al. (1984) “Pathogenesis of Foreign Body Infection,” J. Clin. Invest. 73:1191-1200. [cited by applicant]
Zulianello et al., “The HimA and HimD subunits of integration host factor can specifically bind to DNA as homodimers,” The EMBO Journal, vol. 13, No. 4, Apr. 1, 1994, pp. 1534-1540. [cited by applicant]
Yang, et al., “High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule,” Molecular Medicine, Oct. 27, 2015, Vo. 21, No. Supplement 1, pp. S6-S12. [cited by applicant]
Bakaletz et al., “New strategies to target bacterial biofilms”, 28th Annual North American Cystic Fibrosis Conference (NACFC), Atlanta, GA, Oct. 9-11, 2014 (presentation), 2 pages. [cited by applicant]
Bjarnsholt, “The role of bacterial biofilms in chronic infections,” APMIS (2013) 121(Suppl. 136):1-51. [cited by applicant]
Boles et al., “ [cited by applicant]
Brinkmann et al., “Neutrophil extracellular traps kill bacteria”, Science. 2004; 303(5663):1532-5. doi: 10.1126/science.1092385. [cited by applicant]
Chan, et al., “Growth-related changes in intracellular spermidine and its effect on efflux pump expression and quorum sensing in Burkholderia pseudomallei”, Microbiology, vol. 156, No. 4, Apr. 1, 2010, pp. 1144-1154. [cited by applicant]
Chen et al., “Novel Strategies for the Prevention and Treatment of Biofilm Related Infections,” Int. J. Mol. Sci., vol. 14, Sep. 6, 2013, pp. 18488-18501. [cited by applicant]
Chowdhury, et al., “DNA-Crosslinker Cisplatin Eradicates Bacterial Persister Cells”, Biotechnology and Bioengineering, vol. 113, No. 9, Mar. 10, 2016, pp. 1984-1992. [cited by applicant]
Darvaj et al., “DNABII proteins play a central role in UPEC biofilm structure”, Molecular microbiology. Jun. 2015. 96(6):1119-35, doi: 10.1111/mmi.12994. Epub Apr. 16, 2015. [cited by applicant]
De La Fuente-Nunez et al., “Broad-Spectrum Anti-biofilm Peptide That Targets a Cellular Stress Response,” PLoS Pathog., vol. 10, No. 5, May 2014, pp. 1-12. [cited by applicant]
El-Halfawy, et al., “Chemical Communication of Antibiotic Resistance by a Highly Resistant Subpopulation of Bacterial Cells”, Plos One, Jul. 3, 2013, vol. 8, No. 7, pp. e68874 (1-10). [cited by applicant]
Estelles et al., “A High-Affinity Native Human Antibody Disrupts Biofilm from [cited by applicant]
Feng, et al., “Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection”, Emerging Microbes & Infections, vol. 4, Jun. 3, 2015, pp. 1-16. [cited by applicant]
Goodman et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins”, Mucosal immunology. 2011; 4(6):625-37. Epub Jul. 1, 2011. doi: 10.1038/mi.2011.27. [cited by applicant]
Goodman, “A new immunotherapeutic approach that disperses biofilms, Banff Conference on Infectious Diseases”, Banff, Alberta, Canada, May 18, 2012 (presentation), 9 pages. [cited by applicant]
Goodman, “Making and breaking biofilms”, Ohio Branch American Society for Microbiology Annual Meeting, Columbus, OH, Apr. 11-12, 2014 (presentation), 12 pages. [cited by applicant]
Goodman, “Nucleoprotein complexes in the extracellular matrix are critical for the structural integrity of bacterial biofilms”, 112th General Meeting, American Society for Microbiology, San Francisco, CA, Jun. 18, 2012 … [cited by applicant]
Goodman, “The DNABII family of proteins: Diagnostic markers and therapeutic targets of bacterial biofilms”, International Congress on Bacteriology and Infectious Disease, Baltimore, MD, Nov. 21, 2013, 7 pages. [cited by applicant]
Gustave et al., Biofilms recovered from the sputum of CF patients contain the bacterial protein integration host factor (IHF), 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, Nov. 3-5, 2011 (poster),… [cited by applicant]
International Search Report and Written Opinion dated Feb. 4, 2022, from application No. PCT/US2021/040576, 24 pages. [cited by applicant]
John, et al., “Reversible Daptomycin Tolerance of Adherent Staphylococci in an Implant Infection Model,” Antimicrobial Agents and Chemotherapy (2011) 55(7):3510-3516. [cited by applicant]
Joo, et al., “Molecular Basis of In Vivo Formation by Bacterial Pathogens,” Chemistry & Biology (2012) 19:1503-1513. [cited by applicant]
Junkins, et al., “Autophagy Enhances Bacterial Clearance during [cited by applicant]
Justice et al., “Aberrant Community Architecture and Attenuated Persistence of Uropathogenic [cited by applicant]
Kim et al., “Beta-Arm flexibility of HU from [cited by applicant]
Kirino et al., “Effect of Unusual Polyamines on Cleavage of DNA by Restriction Enzymes,” J. Biochem, 1990, vol. 107, pp. 661-665. [cited by applicant]
Lappann et al., “A dual role of extracellular DNA during biofilm formation of Neisseria meningitidis”, Molecular microbiology. 2010; 75(6):1355-71. doi: 10.1111/j.1365-2958.2010.07054.x. [cited by applicant]
Liao, et al., “Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors”, International Journal of Antimicrobial Agents, vol. 46, Jul. 1, 2015, pp. 42-52. [cited by applicant]
Mahdi et al., “Holliday Junction Resolvases Encoded by Homologous rusA Genes in [cited by applicant]
Malhotra et al., “Defining the functional epitopes of Integration Host Factor (IHF) to develop a novel biofilm-focused immunotherapeutic against nontypeable Haemophilus influenzae-induced chronic and recurrent otitis me… [cited by applicant]
Malhotra et al., “Fine mapping the functional epitopes within integration host factor, a novel therapeutic target for nontypeable Haemophilus influenza-induced diseases of the respiratory tract”, Abst. 12th Annual AMA R… [cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, 20th Annual Midwest Microbial Pathogenesis Meeting. The Ohio State University, Columbus, OH,… [cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, Abst. Seventh Extraordinary International Symposium on Recent Advances in Otitis Media, Stoc… [cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, Seventh Extraordinary International Symposium on Recent Advances in Otitis Media, Stockholm,… [cited by applicant]
Novotny et al., “Antibodies against the majority subunit of Type 1V pili disperse nontypeable Haemophilus influenza biofilms in a LuxS-dependent manner and confer therapeutics resolution of experimental otitis media,” M… [cited by applicant]
Novotny et al., “Structural stability of Burkholderia cenocepacia biofilms is reliant on eDNA structure and presence of a bacterial nucleic acid binding protein”, PloS one. 2013; 8(6):e67629. Epub Jun. 27, 2013. doi: 10… [cited by applicant]
Novotny, “Development of a novel biofilm-focused immunotherapeutic against NTHI-induced otitis media”, 18th International Symposium on Recent Advances in Otitis Media, National Harbor, MD, Jun. 7-11, 2015 (presentation)… [cited by applicant]
Novotny, et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo,” 2016, EBioMedicine 10:33-44. [cited by applicant]
Novotny, et al., “Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media,” npj Vaccines 4:43, Oct. 14, 2019, 12 pages. [cited by applicant]
Priyadarshini et al., “The nucleoid-associated protein HUβ affects global gene expression in Porphyromonas gingivalis”, Microbiology. 2013; 159(Pt 2):219-29.First Published: Feb. 1, 2013. [cited by applicant]
Qu, et al., “Effects of norspermidine on Pseudomonas aeruginosa biofilm formation and eradication”, MicrobiologyOpen, vol. 5, No. 3, Jan. 27, 2016, pp. 402-412. [cited by applicant]
Reffuveille et al., “A Broad-Spectrum Antibiofilm Peptide Enhances Antibiotic Action against Bacterial Biofilms”, Antimicrobial Agents and Chemotherapy, vol. 58, No. 9, Sep. 2014, pp. 5363-5371. [cited by applicant]
Rocco et al. “Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics” Mol Oral Microbiol. Apr. 2017; 32(2):118-… [cited by applicant]
Rouviere-Yaniv et al., “Characterization of a novel, low-molecular-weight DNA-binding protein from [cited by applicant]
Shields, R.C. et al. (2013) “Efficacy of a Marine Bacterial Nuclease against Biofilm Forming Microorganisms Isolated from Chronic Rhinosinusitis,” PLoS ONE 8(2):e55339, 1-13. [cited by applicant]